Literature DB >> 3258651

A hypothetical model of the foreign antigen binding site of class II histocompatibility molecules.

J H Brown1, T Jardetzky, M A Saper, B Samraoui, P J Bjorkman, D C Wiley.   

Abstract

Class II and class I histocompatibility molecules allow T cells to recognize 'processed' polypeptide antigens. The two polypeptide chains of class II molecules, alpha and beta, are each composed of two domains (for review see ref. 6); the N-terminal domains of each, alpha 1 and beta 1, are highly polymorphic and appear responsible for binding peptides at what appears to be a single site and for being recognized by MHC-restricted antigen-specific T cells. Recently, the three-dimensional structure of the foreign antigen binding site of a class I histocompatibility antigen has been described. Because a crystal structure of a class II molecule is not available, we have sought evidence in class II molecules for the structural features observed in the class I binding site by comparing the patterns of conserved and polymorphic residues of twenty-six class I and fifty-four class II amino acid sequences. The hypothetical class II foreign-antigen binding site we present is consistent with mutation experiments and provides a structural framework for proposing peptide binding models to help understand recent peptide binding data.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3258651     DOI: 10.1038/332845a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  277 in total

1.  MHC class II DRB diversity in raccoons (Procyon lotor) reveals associations with raccoon rabies virus (Lyssavirus).

Authors:  Vythegi Srithayakumar; Sarrah Castillo; Rick C Rosatte; Christopher J Kyle
Journal:  Immunogenetics       Date:  2010-10-06       Impact factor: 2.846

Review 2.  Genetic bases of autoimmune hepatitis.

Authors:  Albert J Czaja; Derek G Doherty; Peter T Donaldson
Journal:  Dig Dis Sci       Date:  2002-10       Impact factor: 3.199

Review 3.  Molecular aspects of type 1 diabetes.

Authors:  M A Kelly; M L Rayner; C H Mijovic; A H Barnett
Journal:  Mol Pathol       Date:  2003-02

4.  A possible association between basic amino acids of position 13 of DRB1 chains and autoimmune hepatitis.

Authors:  M Ota; T Seki; K Kiyosawa; S Furuta; K Hino; T Kondo; H Fukushima; K Tsuji; H Inoko
Journal:  Immunogenetics       Date:  1992       Impact factor: 2.846

5.  Interaction of H-2Eb with an IAP retrotransposon in the A20/2J B cell lymphoma.

Authors:  C E Malstrom; A L Kotsenas; B Jones
Journal:  Immunogenetics       Date:  1992       Impact factor: 2.846

Review 6.  Superantigens: biology, immunology, and potential role in disease.

Authors:  C G Drake; B L Kotzin
Journal:  J Clin Immunol       Date:  1992-05       Impact factor: 8.317

7.  Extensive genetic diversity in the HLA class II region of Africans, with a focally predominant allele, DRB1*1304.

Authors:  A V Hill; C E Allsopp; D Kwiatkowski; T E Taylor; S N Yates; N M Anstey; J J Wirima; D R Brewster; A J McMichael; M E Molyneux
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

8.  A gp120 HIV peptide with high similarity to HLA class II beta chains enhances PPD-specific and autoreactive T cell activation.

Authors:  O Pugliese; M Viora; B Camponeschi; P Cordiali Fei; F Caprilli; A Chersi; M Evangelista; A M Di Massimo; V Colizzi
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

Review 9.  The immunogenetics of rheumatoid arthritis.

Authors:  B P Wordsworth; J I Bell
Journal:  Springer Semin Immunopathol       Date:  1992

Review 10.  Dengue fever virus and Japanese encephalitis virus synthetic peptides, with motifs to fit HLA class I haplotypes prevalent in human populations in endemic regions, can be used for application to skin Langerhans cells to prime antiviral CD8+ cytotoxic T cells (CTLs)--a novel approach to the protection of humans.

Authors:  Y Becker
Journal:  Virus Genes       Date:  1994-09       Impact factor: 2.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.